MarginsXMarginsX
Home › Markets › Industrials › PACB

Pacific Biosciences of California Inc. (PACB)

PACB trades on Nasdaq in Industrials, Biotechnology: Laboratory Analytical Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.84
-6.12% on the day
Market cap
$575.8M
Small cap
Revenue · 2025
$160.0M
+3.9% on 2024
Net income · 2025
-$546.4M
-341.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1299130/000129913026000034/0001299130-26-000034-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerPACB on Nasdaq
SectorIndustrials
IndustryBiotechnology: Laboratory Analytical Instruments
CountryUnited States
IPO year2010
SEC CIK0001299130
SEC industry codeLaboratory Analytical Instruments
Incorporated inDE

Financials · 2025

LineValue
Revenue$160.0M
Net income-$546.4M
Operating income-$553.9M
Net margin-341.5%
Operating margin-346.2%
Revenue growth+3.9%
Cash$63.7M
Total assets$784.1M
P/E (computed)Net income was not positive
P/S (computed)3.6×

Warning signs

Cash runway
4.9 months
$55.9M cash at September 30, 2026
Share count, 1 year
+3.6%
2025-10-31 to 2026-10-31 · +17.0% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$1.3M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$55.9M cash; operating cash flow -$34.2M a quarter.Report 2026-09-30
Shares outstanding312,926,730 (2026-10-31); 301,907,431 a year earlier; 267,443,887 three years earlier.Cover page 2026-10-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-11-10
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Mateo, California, United StatesPCAOB Form AP 2026-03-18
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $1.3M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$40.6M-$37.8M-$37.6M$55.9MNo debt tags$161.4M10-Q 2026-11-05
Q2 2026
2026-06-30
$39.0M-$44.7M-$35.6M$61.0MNo debt tags$159.3M10-Q 2026-08-06
Q1 2026
2026-03-31
$37.2M-$8.3M-$44.7M$56.3MNo debt tags$160.0M10-Q 2026-05-08
Q4 2025
2025-12-31
$44.6M-$40.4M-$19.1M$63.7MNo debt tags$160.0M10-K 2026-02-25
Q3 2025
2025-09-30
$38.4M-$38.0M-$18.7M$56.5MNo debt tags$154.6M10-Q 2026-11-05
Q2 2025
2025-06-30
$39.8M-$41.9M-$29.4M$54.8MNo debt tags$156.1M10-Q 2026-08-06
Q1 2025
2025-03-31
$37.2M-$426.1M-$44.1M$58.5MNo debt tags$152.4M10-Q 2026-05-08
Q4 2024
2024-12-31
$39.2M$2.4M-$30.6M$55.4M$0$154.0M10-K 2026-02-25

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-11-10
Latest annual report10-K2026-02-25
Latest quarterly / interim10-Q2026-11-05
Latest current report
FORM 8-K
8-K2026-11-10
Latest proxyDEFA14A2026-05-22

Source: SEC EDGAR submissions feed, 977 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-13.3%
1 month-4.4%
3 months+70.4%
Year to date+4.8%
1 year+20.2%
From 52-week high-32.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Laboratory Analytical Instruments

TickerCompanyPriceDayMarket cap
CTKBCytek Biosciences Inc.$5.63-3.60%$736.3M
NAUTNautilus Biotechnology Inc.$2.10-9.48%$267.5M
LABStandard BioTools Inc.$0.6210-12.21%$245.2M
ALMRAlamar Biosciences Inc.$30.55-0.84%$2.1B
QTRXQuanterix Corporation$2.84-3.07%$134.8M
SEERSeer Inc.$1.48-5.73%$82.6M
TXG10x Genomics Inc.$54.99-5.50%$7.2B
HBIOHarvard Bioscience Inc.$8.91-5.96%$40.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier